MedTrace Logo

YAZ, Oral Contraceptive Registration in China

NCT00819312 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 675

Last updated 2013-01-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive YAZ in healthy Chinese women.

Conditions

  • Contraception

Interventions

DRUG

YAZ (SH T00186, BAY86-5300)

20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • China
  • Hong Kong

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819312 on ClinicalTrials.gov